Use of the CIGB-247-V vaccine candidate in the treatment of Age-Related Macular Degeneration

Trial Profile

Use of the CIGB-247-V vaccine candidate in the treatment of Age-Related Macular Degeneration

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2016

At a glance

  • Drugs CIGB 247 (Primary) ; Bevacizumab
  • Indications Age-related macular degeneration
  • Focus Adverse reactions
  • Acronyms CELIMAR
  • Most Recent Events

    • 14 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top